Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Update

Virios Therapeutics, Inc. (NASDAQ:VIRI) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 469,900 shares, a drop of 19.0% from the August 31st total of 580,300 shares. Based on an average daily volume of 992,300 shares, the days-to-cover ratio is currently 0.5 days.

Virios Therapeutics Stock Up 3.9 %

NASDAQ:VIRI opened at $0.19 on Friday. The company has a market capitalization of $5.19 million, a PE ratio of -0.69 and a beta of 1.59. Virios Therapeutics has a 52-week low of $0.16 and a 52-week high of $1.04. The stock’s 50 day moving average price is $0.20 and its 200 day moving average price is $0.29.

Virios Therapeutics (NASDAQ:VIRI) last announced its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. During the same quarter in the previous year, the business earned ($0.08) EPS. As a group, sell-side analysts anticipate that Virios Therapeutics will post -0.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Maxim Group initiated coverage on shares of Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 target price for the company. HC Wainwright decreased their price objective on shares of Virios Therapeutics from $0.40 to $0.20 and set a “neutral” rating for the company in a research note on Friday, August 9th.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.